Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCost-Benefit AnalysisFemaleHumansMaleMiddle AgedConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rate